• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Progress in the treatment of multiple myeloma with daratumumab].[达雷妥尤单抗治疗多发性骨髓瘤的研究进展]
Zhonghua Xue Ye Xue Za Zhi. 2021 Mar 14;42(3):260-264. doi: 10.3760/cma.j.issn.0253-2727.2021.03.016.
2
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.来那度胺联合地塞米松添加达雷妥尤单抗或硼替佐米治疗新诊断多发性骨髓瘤的成本效果分析。
J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691.
3
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
4
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.达雷妥尤单抗联合来那度胺和地塞米松治疗初治多发性骨髓瘤。
N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.
5
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
6
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.为了实现骨髓瘤的有效免疫治疗：来那度胺联合人 CD38 单克隆抗体达雷妥尤单抗增强骨髓瘤细胞的消除。
Haematologica. 2011 Feb;96(2):284-90. doi: 10.3324/haematol.2010.030759. Epub 2010 Nov 25.
7
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于复发多发性骨髓瘤的1/2期研究。
Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.
8
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.在接受达雷妥尤单抗治疗的患者中，单核细胞和粒细胞降低骨髓瘤细胞上 CD38 的表达水平。
Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.
9
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.EMA 对达雷妥尤单抗治疗多发性骨髓瘤成人患者的评估。
Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25.
10
Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗新诊断的依赖透析的多发性骨髓瘤患者后的肾脏恢复情况
CEN Case Rep. 2022 May;11(2):265-268. doi: 10.1007/s13730-021-00668-w. Epub 2021 Nov 24.

本文引用的文献

1
Use of daratumumab in high risk multiple myeloma: A meta-analysis.达雷妥尤单抗在高危多发性骨髓瘤中的应用：一项荟萃分析。
EJHaem. 2020 Jul 2;1(1):267-271. doi: 10.1002/jha2.47. eCollection 2020 Jul.
2
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.评估达雷妥尤单抗治疗伴有高危细胞遗传学因素的多发性骨髓瘤患者的疗效：系统评价和荟萃分析。
JAMA Oncol. 2020 Nov 1;6(11):1759-1765. doi: 10.1001/jamaoncol.2020.4338.
3
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
4
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.皮下注射与静脉注射达雷妥尤单抗治疗复发或难治性多发性骨髓瘤患者（COLUMBA）：一项多中心、开放标签、非劣效性、随机、3期试验
Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23.
5
Immunotherapy for Multiple Myeloma.多发性骨髓瘤的免疫疗法
Cancers (Basel). 2019 Dec 12;11(12):2009. doi: 10.3390/cancers11122009.
6
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
7
Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.多发性骨髓瘤患者中乙型肝炎病毒的再激活
Cancers (Basel). 2019 Nov 19;11(11):1819. doi: 10.3390/cancers11111819.
8
Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗未接受移植的东亚多发性骨髓瘤患者：随机 3 期 ALCYONE 试验的亚组分析。
Ann Hematol. 2019 Dec;98(12):2805-2814. doi: 10.1007/s00277-019-03794-9. Epub 2019 Oct 16.
9
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
10
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.达雷妥尤单抗、泊马度胺和地塞米松治疗复发或难治性骨髓瘤患者的临床疗效：在耐药患者中再次使用达雷妥尤单抗的效果。
Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.

[Progress in the treatment of multiple myeloma with daratumumab].

作者信息

Lu J

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2021 Mar 14;42(3):260-264. doi: 10.3760/cma.j.issn.0253-2727.2021.03.016.

DOI:10.3760/cma.j.issn.0253-2727.2021.03.016
PMID:33910316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8081942/
Abstract
摘要